Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion type Assertion NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_head.
- NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_provenance.
- NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion evidence source_evidence_literature NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_provenance.
- NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion SIO_000772 23307549 NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_provenance.
- NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion wasDerivedFrom befree-20150227 NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_provenance.
- NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_assertion wasGeneratedBy ECO_0000203 NP519010.RAW2ghxVzz1_Zrc-n3u8svSeHNLpiUmEZ044FLW6DKvxI130_provenance.